Eventide Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$426K Buy
836
+310
+59% +$164K 0.01% 267
2026
Q2
$277K Buy
+526
New +$269K ﹤0.01% 266
2018
Q4
– Sell
-33,000
Closed -$7.07M – 144
2018
Q3
$7.07M Sell
33,000
-13,000
-28% -$3.26M 0.26% 90
2018
Q2
$12.9M Buy
46,000
+21,000
+84% +$3.69M 0.53% 66
2018
Q1
$2.92M Buy
+25,000
New +$3.09M 0.14% 100

Other funds holding MDGL

Eventide Asset Management's MDGL Position: Q3 2026 in Review

Eventide Asset Management increased its Madrigal Pharmaceuticals (MDGL) stake by 59% in Q3 2026, buying an estimated $164K and bringing the position to 836 shares worth $426K. The position accounts for 0.01% of the portfolio, ranked #267.

Eventide Asset Management first reported a position in MDGL in Q1 2018 and has held it in 5 quarters since. The position peaked at $12.9M in Q2 2018. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Eventide Asset Management held 836 shares of Madrigal Pharmaceuticals worth $426K as of Q3 2026.
  • Eventide Asset Management bought 310 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $164K.
  • Madrigal Pharmaceuticals made up 0.01% of Eventide Asset Management's portfolio in Q3 2026, its #267 holding.
  • Eventide Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2018 and has held it in 5 quarters since.
  • Eventide Asset Management's Madrigal Pharmaceuticals position peaked at $12.9M in Q2 2018.
  • 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.